Ranjit Manchanda is a Professor at Wolfson Institute of Preventive Medicine, Barts CRUK Cancer Centre, QMUL, and Consultant Gynaecological Oncologist at Barts and the Royal London Hospital, London, UK.

Ranjit’s research interests are focused around Targeted Precision Prevention. This includes population-based germline testing, mainstreaming and precision medicine approaches for risk prediction, stratification, and targeted screening & cancer prevention. He has a keen research interest in health economic issues related to his areas of research. He was awarded an NHS Innovation Accelerator (NIA) Fellowship for Population Genetic Testing. He is the Principal Investigator on the PROTECTOR trial, PROMISE Pilot study, GCaPPS trial, RRESDO and SIGNPOST study.

He is co-Lead for the Cancer Prevention Theme at the Barts CRUK Cancer Centre. He leads the high-risk women’s Precision Prevention Clinic at Barts Health and is chair of the London Cancer High risk Gynaecological Cancer MDT. He is a member of the NCRI Ovarian Cancer Surgical Sub group and chairs the Barts Health Gynae-oncology trials group. He is the Integrated Academic Training Programme Director, London Specialty School of Obstetrics & Gynaecology, Health Education England; and Lead for the RCOG Advanced Professional Module (APM) in Clinical Research for North Central and North East London. He is a member of number of other advisory bodies and oversight committees. He has served as President of the European Network of Young Gynaecological Oncologists (ENYGO) and member of the European Society of Gynaecological Oncology (ESGO) Council from 2011-2013.